United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fraxinus excelsior) pollen 50,000bu/ml solution for skin prick test (allergopharma - ash (fraxinus excelsior) pollen allergen extract - solution for skin-prick test

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - solidago canadensis pollen (unii: 644cz16ir5) (solidago canadensis pollen - unii:644cz16ir5) - equus caballus skin 20000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), aspergillus repens (unii: sq89e6lome) (aspergillus repens - unii:sq89e6lome), aspergillus flavus var. oryzae (unii: q6z8uk5r3g) (aspergillus flavus var. oryzae - unii:q6z8uk5r3g), aspergillus terreus (unii: qbn8k7055x) (aspergillus terreus - unii:qbn8k7055x) - fraxinus americana pollen 0.05 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 0.1 ir/ml (betula alba pollen extract); allergen extracts 1 ir/ml (betula alba pollen extract); allergen extracts 10 ir/ml (betula alba pollen extract) - solution for injection - active: allergen extracts 0.1 ir/ml (betula alba pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ir/ml (betula alba pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ir/ml (betula alba pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 10 ir/ml (betula alba pollen extract) - solution for injection - 10 ir/ml - active: allergen extracts 10 ir/ml (betula alba pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 0.1 ic/ml (chenopodium album pollen extract); allergen extracts 1 ic/ml (chenopodium album pollen extract); allergen extracts 10 ic/ml (chenopodium album pollen extract) - solution for injection - active: allergen extracts 0.1 ic/ml (chenopodium album pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (chenopodium album pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (chenopodium album pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 10 ic/ml (chenopodium album pollen extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (chenopodium album pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 0.1 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts); allergen extracts 1 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts); allergen extracts 10 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) - solution for injection - active: allergen extracts 0.1 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 10 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 1 ic/ml (plantago lanceolata pollen extract); allergen extracts 1 ic/ml (plantago lanceolata pollen extract); allergen extracts 10 ic/ml (plantago lanceolata pollen extract) - solution for injection - active: allergen extracts 1 ic/ml (plantago lanceolata pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (plantago lanceolata pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (plantago lanceolata pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water